Evidence map›Paper›PMID 38424104›Full record

ArticleScientific reports2024

IFN-γ decreases PD-1 in T lymphocytes from convalescent COVID-19 patients via the AKT/GSK3β signaling pathway.

Meijuan Song, Xiangqun Liu, Weiyu Shen, Zhengxia Wang, Jingjing Wu, Jingxian Jiang, Yanan Liu, Tingting Xu, Tao Bian, Mingshun Zhang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Meijuan Song *Department of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Xiangqun Liu *Department of Respiratory and Critical Care Medicine, The Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University, Xuzhou, China.
Weiyu Shen *Department of Respiratory and Critical Care Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Zhengxia WangDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Jingjing WuDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Jingxian JiangDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Yanan LiuDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Tingting XuDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Tao BianDepartment of Respiratory and Critical Care Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Mingshun ZhangJiangsu Province Engineering Research Center of Antibody Drug, NHC Key Laboratory of Antibody Technique, Department of Immunology, Nanjing Medical University, Nanjing, China. mingshunzhang@njmu.edu.cn.
Wei SunDepartment of Respiratory and Critical Care Medicine, Xishan People's Hospital of Wuxi City, Wuxi, China. sunweiwx@163.com.
Mao HuangDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China. hm6114@163.com.
Ningfei JiDepartment of Respiratory and Critical Care Medicine, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China. jiningfei@163.com.
Nanjing Medical University · CNWuxi People's Hospital · CNXuzhou Medical College · CN

Funding

Jiangsu Provincial Key Research and Development Program BE2020616
6 · The paper itself

Abstract

Post-COVID-19 syndrome may be associated with the abnormal immune status. Compared with the unexposed age-matched elder group, PD-1 in the CD8

Indexed as

CD8-Positive T-LymphocytesCOVID-19AgedGlycogen Synthase Kinase 3 betaHumansInterferon-gammaPost-Acute COVID-19 SyndromeProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktSignal TransductionGlycogen Synthase Kinase 3 betaIFNG protein, humanInterferon-gammaPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktCD8+ T cellsConvalescent patientsCoronavirus disease 2019IFN-γPD-1

Identifiers

PMID38424104
PMCPMC10904811
OpenAlexW4392284038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.